Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/emeOCfbwocfDlrABopII

March 4, 2013
Sign upForwardArchiveAdvertiseRead more at SmartBrief.com
News for nuclear medicine and molecular imaging professionals
 
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.

  Top Story 
  • Canada has an isotope plan, but will it deliver?
    The Canadian government has allotted $24.3 million to advance production of isotopes without the use of highly enriched uranium by 2016, but it's possible the system may not deliver as expected. Timothy Meyers of TRIUMF, one of the three institutes awarded funding, acknowledged there are still challenges to be met. Meyers said his organization expects the technology will be ready by 2016, but the health care community should be prepared for a possible temporary shortage that year. The Globe and Mail (Toronto) (tiered subscription model) (2/28) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
Is Pricing Low Your Strategy to Success? Think again.
Pricing is the heart of a business. It affects everything you do and is affected by everything you do. Economists talk of supply and demand as key factors behind pricing—successful entrepreneurs manipulate demand by making their products more desirable. These six steps will help you determine the right price for your product or service, read the article and learn how to get pricing right.

  Clinical News & Research 
  • Study: Retinal abnormalities linked to Alzheimer's
    Data from an Australian study indicate that patients with Alzheimer's disease have abnormalities in retinal vascular parameters, such as a higher arteriole-to-venule ratio and narrower veins, according to a study published in Translational Psychiatry. PiB-PET imaging also showed that people without the disease who had high levels of neocortical plaque accumulation also manifest some RVP changes, suggesting they may have preclinical Alzheimer's. Eye tests may present another option for diagnosing Alzheimer's, although not as a stand-alone method, researchers said. Medscape (free registration) (3/1) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  

  Industry Report 
  • Agfa set to showcase latest Impax software
    Agfa HealthCare is preparing to introduce its Impax CV Web+ software at a cardiology meeting this month. The company said the software is a standards-based, vendor-neutral system that allows for access to an integrated cardiovascular information platform's results and modalities, including nuclear cardiology data. The product is expected to be available later this year. AuntMinnie.com (free registration) (2/28) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • Report projects growth for optical imaging
    A report from Markets and Markets showed the value of the optical imaging technology market approached $916 million last year. The report projects the market could be valued at $1.9 billion by 2018. The study assessed various technologies, including hyper spectral imaging and near-infrared spectroscopy. BeckersASC.com (3/1) LinkedInFacebookTwitterEmail this Story
  International Developments 
  Health Policy 
  • Lawmakers reintroduce bill seeking to stop imaging fee cuts
    Lawmakers have revived the Diagnostic Imaging Services Access Protection Act. Similar to previous versions of the measure, the bill seeks to block a 25% cut in Medicare payments for the reading of advanced diagnostic imaging results. The bill would cover tests conducted on the same patient in a single procedure. HealthImaging.com (2/28) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  • Former FDA chief: Reform rules for clinical trials
    Changing the FDA's burdensome requirements for clinical trials could help double the number of new drug approvals, former FDA Commissioner Andrew von Eschenbach and University of Chicago public policy professor Tomas Philipson write. Phase III studies are unnecessarily large and cumbersome for more precise and personalized medicine. Adopting smaller, quicker adaptive studies with post-market oversight would mean greater innovation and a better economy. Bloomberg (2/28) LinkedInFacebookTwitterEmail this Story
 
  From SNMMI 
  • JNM and JNMT launch new, full-text mobile journal application
    SNMMI has released a full-text mobile application for The Journal of Nuclear Medicine and the Journal of Nuclear Medicine Technology. Compatible with iOS devices (iPad, iPod Touch and iPhone), the applications can be downloaded from the iTunes App Store. The application is free for SNMMI members and journal subscribers, and nonmembers can download and access the application for no charge during an extended trial period. LinkedInFacebookTwitterEmail this Story
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

  SmartQuote 
The man who insists upon seeing with perfect clearness before he decides, never decides. Accept life, and you must accept regret."
--Henri Frédéric Amiel,
Swiss philosopher, poet and critic


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
   
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Advertise
Account Director:   Meryl Harold   (202) 407-7828
 
Read more at SmartBrief.com
 
 
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.®  Legal Information